Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

Income Statement

Follow revenue through to earnings.

Revenue

$42.17M

FY 2025 · Annual

-84.2% YoY

Operating Income

-$179.53M

FY 2025 · Annual

Net Income

-$170.29M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue326.55M211.04M257.24M266.96M42.17M
Cost of Revenue57.59M70.08M158.99M117.55M17.74M
Gross Profit268.96M140.96M98.25M149.41M24.43M
Gross Margin82.4%66.8%38.2%56.0%57.9%
Research & Development363.11M199.36M109.44M93.34M104.96M
Selling, General & Admin169.71M198.48M185.62M150.44M99M
Operating Expenses532.82M397.84M301.45M261.07M203.97M
Depreciation & Amortization3.45M3.7M3.79M5.28M3.92M
EBITDA(260.69M)(255.58M)(193.94M)60.94M(170.2M)
EBITDA Margin-79.8%-121.1%-75.4%22.8%-403.6%
Operating Income(263.86M)(256.88M)(203.2M)(111.67M)(179.53M)
Operating Margin-80.8%-121.7%-79.0%-41.8%-425.7%
Interest Income00000
Interest Expense22.96M32.47M40.54M27.16M9M
Other Income / Expenses(23.24M)(34.87M)(35.07M)140.17M(3.59M)
Income Before Tax(287.1M)(291.75M)(238.27M)28.51M(183.12M)
Pre-Tax Margin-87.9%-138.2%-92.6%10.7%-434.2%
Income Tax Expense00(380K)00
Net Income(287.1M)(291.75M)(237.89M)28.51M(170.29M)
Net Margin-87.9%-138.2%-92.5%10.7%-403.8%
EPS (Basic)(3.81)(3.76)(2.53)0.25(1.45)
EPS (Diluted)(3.81)(3.76)(2.53)0.25(1.45)
Weighted Avg Shares75.45M77.63M94.16M114.55M120.37M
Weighted Avg Shares (Diluted)75.45M77.63M94.16M114.83M120.37M

CHRS Earnings Waterfall · TTM

NASDAQ:CHRS · Revenue to Net Income

Key Ratios

EPS$-1.28
Gross Margin59.9%
Net Margin-326.8%
P/E Ratio-1.1
P/S Ratio14.2

Analysis

$46.9M of revenue converted into -$151.7M of net income for the selected period. Gross margin is 59.9% and net margin is -326.8%, showing how much revenue survives after costs and taxes. EPS is $-1.28, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportOct 29, 2026
8-KCurrent reportAug 28, 2026
424B5424B5 filingAug 28, 2026

How much revenue does CHRS generate?

Coherus Oncology, Inc. (CHRS) reported $42.17M of revenue in fiscal 2025.

Is CHRS profitable?

Coherus Oncology, Inc. (CHRS) reported -$170.29M of net income, with a net margin of -403.8%.